Boan Biotech to Attend PEGS Boston 2023 with Its Novel ADC BA1302

Yantai, China, May 15, 2023—Boan Biotech is to present the results of its research on BA1302, a novel CD228-directed antibody drug conjugate (ADC) developed by the company, as a poster at the 19^th Essential Protein Engineering & Cell Therapy Summit, known as PEGS Boston Summit 2023 or simply PEGS Boston 2023.

PEGS Boston 2023 will be held during May 15-19, 2023 in Boston, MA. It is the leading biologics event with comprehensive programming covering all aspects of biologic drug development, including presentations on protein and antibody engineering, immunotherapy, oncology, expression, analytics, immunogenicity, and more.

BA1302 demonstrated excellent stability and antitumor potential both in vitro and in vivo

BA1302 is a novel CD228-directed ADC developed by Boan Biotech using its ADC platform technology.

First found in melanoma, CD228 is a GPI anchored glycoprotein that plays a role in tumor cell proliferation and migration. It is highly expressed in a variety of solid tumors such as melanoma, mesothelioma, colon cancer, breast cancer, and pancreatic cancer, and has low expression in normal tissues. Therefore, CD228 has high specificity in terms of expressing in tumors. The antibody of BA1302 is obtained from the company’s proprietary human antibody transgenic mice BA-huMab^®. It has higher binding specificity, and binds with the membrane form of CD228 only, not with sMF12, which is its soluble form. The chemical part of BA1302 is BNLD11, a linker-payload screened by the company stable both in vitro and in vivo.

The preclinical study shows that BA1302 exhibits a good antitumor effect in various tumor models such as lung cancer, gastric cancer, and melanoma. It demonstrates good safety and tolerance in the toxicological pretests on cynomolgus monkeys with the Maximum Tolerated Dose (MTD) being over 10mg/kg. This indicates strong therapeutic potential for the drug if used in clinical settings.

BA1302 is in the preclinical study phase, and is expected to be the first-in-class product in China. no other ADC candidates with the same target have been reported for clinical trials in China.

Advantages of Boan Biotech’s ADC platform

As a novel type of drug, ADC is like a biological missile that effectively attacks target cells through the precise delivery of a chemical toxin linked to an antibody. Boan Biotech’s ADC platform covers the entire process of drug discovery, development and commercialization. Specifically, the drug discovery aims to design a more stable and effective linker-payload that reduces the non-specific release of toxin in the circulatory system. This allows the toxin of ADC to be accurately released in the target tissues, to complete the targeted and precise delivery of the payload. Such a design helps to increase the ADC’s safety and expands its therapeutic window. This technology has been used for multiple ADCs under development. Boan Biotech will leverage the strength of its ADC platform to develop more novel ADCs that have the potential for clinical use.

BA1301 for Injection, the company’s first novel ADC under development, is already in clinical trials. It is designed to treat advanced solid tumors expressing Claudin18.2, such as advanced gastric cancer, gastroesophageal junction adenocarcinoma, and pancreatic cancer, etc.